Kari Nadeau, MD, PhD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Kari Nadeau, MD, PhD sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting early-phase tilt upper half by trial count

Kari Nadeau, MD, PhD: 1 sponsored US clinical trial, none currently recruiting.

Kari Nadeau, MD, PhD sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Eczema, Infantile, with 1 trials.

Mid-pack sponsor footprint

Kari Nadeau, MD, PhD is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Seal, Stopping Eczema and Allergy Study

NCT03742414

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Eczema, Infantile 1
Atopic Dermatitis Eczema 1
Eczema 1
Atopic Dermatitis 1

How the Kari Nadeau, MD, PhD early-phase archive is shaped

1 indexed studies, none listed as recruiting (0% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Eczema, Infantile (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Kari Nadeau, MD, PhD: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Kari Nadeau, MD, PhD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Kari Nadeau, MD, PhD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Kari Nadeau, MD, PhD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kari Nadeau, MD, PhD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kari Nadeau, MD, PhD page

1 registered trials is a research-attention snapshot, not an endorsement of Kari Nadeau, MD, PhD or any single study.

  • None of Kari Nadeau, MD, PhD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Eczema, Infantile is the condition Kari Nadeau, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Eczema, Infantile trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kari Nadeau, MD, PhD pipeline card: 1 registered trials from official public datasets.Report a data error.